A New in Vitro Human Model to Study MOGAD Physiopathology: The MOGAXON Project
Principal Investigators | Álvaro Cobo-Calvo, MD, PhD and García León
Institutions | Multiple Sclerosis Center of Catalonia (CEMCAT), Vall d’Hebron and University of Malaga (Spain)
Aim | To establish a new in vitro human model comprising an all-human induced pluripotent stem cells (hiPSC)-derived oligodendrocytes co-cultured with neurons that could serve as the bases to reveal new MOGAD-specific mechanisms, a previous essential step before developing novel therapeutic strategies.
NMOSD and MOGAD in Montenegro: Clinical Aspects, Pain, and Community Impact
Principal Investigator | Sanja Gluscevic
Institution | Clinical Centre of Montenegro, Neurology Clinic, University of Montenegro
Aim | To provide a comprehensive understanding of NMOSD and MOGAD in Montenegro, with a focus on clinical aspects, pain, and the impact on the community. The findings of this study can potentially contribute to the development of better strategies for diagnosis, treatment, and support for patients with NMOSD and MOGAD in the country.
Funds Awarded | $5,000
Grant Type | SPARK Grant – This grant was made possible with support from Terry & Greg Clark of The Dorchester Foundation
Validating the TRIPS-A Scoring Tool for Relapse Prediction in MOGAD
Principal Investigator | Ahmed Obeidat
Institution | Medical College of Wisconsin (United States)
Aim I | To develop and apply a scoring tool to predict subsequent relapses after an initial attack in people with myelin oligodendrocyte glycoprotein antibody disease.
Aim II | To compare serum levels of neurofilament light (NfL), a marker of neuroaxonal damage, cross-sectionally, between patients falling into the high score category (potentially relapsing) versus those falling into the lower score category (potentially monophasic).
Aim I | Develop longitudinal database and biorepository for MOG Antibody Disease (MOGAD) patients at the Stanford Neuroimmunology Center, including multi-center collaboration. Demographic, clinical outcomes, biochemical (including MOG-IgG serial titers, presence of co-neuronal antibodies), neuroimaging and neuropsychological outcomes, when available.
Aim II | To determine if MOG IgG positivity or titer predicts index event severity or relapse
Aim III | To correlate MOG IgG serostatus with serum and cerebrospinal fluid (CSF) immune profiles (pleocytosis, oligoclonal bands, paired serum/CSF IL-6, TNF-alpha, T and B lymphocyte profiles) to inform immunopathogenesis and treatment